Table 1.
Distribution of endpoints from the landmark analysis at 3 years (n = 1364)*
| No. (%) of cumulative DM events |
No. (%) of cumulative GCTF events |
No. (%) of cumulative PCSDs |
|||||||
| Time to event, y | Control arm | Experimental arm | Total | Control arm | Experimental arm | Total | Control arm | Experimental arm | Total |
| ≤ 1 | 2 (1) | 2 (2) | 4 (1.5) | 45 (12) | 32 (11) | 77 (11.4) | — | — | — |
| >1 to 2 | 25 (16) | 9 (9) | 34 (13.1) | 103 (27) | 58 (20) | 161 (23.9) | — | — | — |
| >2 to 3 | 61 (39) | 27 (27) | 88 (34.0) | 235 (62) | 177 (60) | 412 (61.0) | — | — | — |
| >3 to 4 | 74 (47) | 38 (38) | 112 (43.2) | 267 (70) | 199 (67) | 466 (69.0) | 17 (16) | 7 (9) | 24 (13.1) |
| >4 to 5 | 85 (54) | 52 (51) | 137 (52.9) | 295 (78) | 224 (76) | 519 (76.9) | 33 (31) | 20 (26) | 53 (29.0) |
| >5 to 6 | 98 (62) | 65 (64) | 163 (62.9) | 315 (83) | 240 (81) | 555 (82.2) | 47 (44) | 31 (41) | 78 (42.6) |
| >6 to 7 | 114 (72) | 70 (69) | 184 (71.0) | 341 (90) | 256 (87) | 597 (88.4) | 55 (51) | 37 (49) | 92 (50.3) |
| >7 to 8 | 125 (79) | 82 (81) | 207 (79.9) | 355 (93) | 267 (91) | 622 (92.2) | 67 (63) | 45 (59) | 112 (61.2) |
| >8 to 9 | 136 (86) | 88 (87) | 224 (86.5) | 367 (97) | 275 (93) | 642 (95.1) | 82 (77) | 55 (72) | 137 (74.9) |
| >9 to 10 | 147 (93) | 95 (94) | 242 (93.4) | 375 (99) | 284 (96) | 659 (97.6) | 92 (86) | 64 (84) | 156 (85.3) |
| >10 to 11 | 151 (96) | 98 (97) | 249 (96.1) | 379 (99) | 287 (97) | 666 (98.7) | 101 (94) | 69 (91) | 170 (92.9) |
| >11 to 12 | 157 (99) | 99 (98) | 256 (98.8) | 379 (99) | 293 (99) | 672 (99.6) | 104 (97) | 73 (96) | 177 (96.7) |
| >12 | 158 (100) | 101 (100) | 259 (100) | 380 (100) | 295 (100) | 675 (100) | 107 (100) | 76 (100) | 183 (100) |
*
Time to event was from the date of random assignment to distant metastasis, general clinical treatment failure, or prostate cancer–specific death. DM = distant metastasis; GCTF = general clinical treatment failure; PCSDs = prostate cancer-specific deaths; — = no PCSDs.